




The human heart is undeniably pulsatile, yet over **600,000 patients** each year do not have the benefit of a heartbeat during open-heart surgery or circulatory support.



A Billion Dollar Addressable Market


This is a device that truly replicates the function of the heart during temporary extracorporeal therapy.

VENTRIFLO™ True Pulse Pumps are the only extracorporeal pumps designed to mimic the human heartbeat.



VENTRIFLO pumps have the unique ability to deliver blood pressure and flow profiles that re-create the human heartbeat for patients requiring cardiopulmonary (“heart lung”) support.

Today’s extracorporeal blood pumps simply do not mimic the human heart.



THE IMPACT:
30% of capillaries
do not open during
continuous flow
perfusion.

IT MATTERS:

In Cardiopulmonary Bypass (“CPB”): **30-50% of patients receiving open-heart surgery suffer from lingering issues:** acute kidney injury, gastrointestinal bleeding, neurological dysfunction (“pump head”) and/or lung dysfunction.

In Extracorporeal Membrane Oxygenation (“ECMO”): **40-60% of patients receiving multi-day cardiopulmonary support do not survive this procedure.**

Pulsatile blood flow improves microcirculation, reducing complications, improving patient outcomes and increasing the likelihood of survival.

VENTRIFLO is a privately held angel-backed company based in Pelham, NH.

VENTRIFLO is seeking \$7M in structured financing to achieve 510(k) clearance and First In Human (FIH) studies in the next 18 months.



VENTRIFLO™ True Pulse Pumps are under development, for investigational use only, and are not available for commercial sale.

VENTRIFLO and the VENTRIFLO logo are trademarks of Design Mentor, Inc. Copyright © 2017 Design Mentor, Inc.

VENTRIFLO PERFORMANCE:

- Working with leading centers:



Wallace H. Coulter Department of Biomedical Engineering
Georgia Tech College of Engineering and Emory School of Medicine



- 14 successful animal studies, including prolonged (6 hour) CPB times showing superior microcirculation
- 5 successful blood studies demonstrate superior resistance to clotting

VENTRIFLO Pumps achieve > 80% proper capillary perfusion (similar to baseline) vs. < 40% with current standards.

OPPORTUNITY:

Single-use pump consumables with > 90% gross margin with established reimbursement codes.

- An **executive team with over 150 years** of experience in large and emerging medical device companies
- **Advisory board with over 200 years** clinical and research experience
- 5 patents across US, Canada, Japan and EU (validated in 13 countries)

CONTACT:

Doug Vincent
DougVincent@VentriFlo.com
603-459-0710

LEARN MORE:

www.VentriFlo.com



VENTRIFLO
True Pulse Pumps